

press release

mergermarket Pharma M&A Round Up Q1 2009
20 April 2009, for immediate release

Contact:

Europe & North America:
Hannah Bagshawe
hannah.bagshawe@mergermarket.com
Tel: +44 20 7059 6118

Asia-Pacific:
Seye Im
seye.im@mergermarket.com
Tel: +852 2158 9701

mergermarket Pharma M&A Round Up Q1 2009

Contents

p. 3 - 7	League Tables
p. 8 - 9	Top Deals
p. 10 - 11	Expected Deals
p. 12 - 15	M&A Activity
p. 16	Criteria
p. 17	About mergermarket

Global Trends in Life sciences & Healthcare

- The first quarter of 2009 has significantly outperformed the entire fiscal 2008, with a total value of US\$ 166bn, compared to US\$ 14.7bn for Q1 2008, and US\$ 114bn for the whole year. What we have seen recently is companies trying to increase their revenue generation through acquisitions. Biotech companies are also focusing on acquiring products in various stages of development which will be able to hit the market in the near future. The overall deal count has decreased by 23.7% from the previous quarter, and by 45.4% from Q1 2008; an anticipated trend in the time of consolidation.

Mega-deals – A Trend For 2009?

- 2009 began with three mega-deals in the Life Sciences & Healthcare sector. Pfizer acquired Wyeth for a total consideration of US\$ 64bn; Roche Holding acquired the remaining 44.1% stake in Genentech that it did not already own, a deal size that amassed US\$ 47bn; and Merck & Co spent US\$ 43bn to acquire Schering-Plough. Is the trend of mega deals likely to continue in the sector during 2009? Some insiders are not seeing more Life Sciences & Healthcare mega-deals on the horizon. They believe that it would simply be difficult to top valuations of the transactions announced during the first quarter of 2009. In addition, a number of the big pharma players, like pharmaceutical giant, GlaxoSmithKline Plc, have expressed a lack of interest in making big acquisitions, while Sanofi Aventis has been sticking to smaller-scale deals recently, including Medley S/A Industria Farmaceutica and BiPar Sciences. Still, this does not mean that in 2009 M&A activity in the sector will experience a decrease. Pharma companies are trying to find ways to grow as they gear for looming patent expirations that threaten their current growth.
- Mid-market transactions and deals valued below US\$ 5bn may be the next lucrative M&A area in the Life Sciences & Healthcare sector. Stiefel Laboratories, the private US-based dermatology pharmaceutical company, using the advisory arm of Blackstone Group to advise it as the company explores sales options. Johnson & Johnson, the listed US-based manufacturer of health care products, has expressed interest in the company, which has an estimated price tag of US\$ 3bn to US\$ 4bn. Bristol-Myers Squibb, the listed US-based biopharmaceutical company, reportedly has a healthy cash position and is strategically looking to make a number of small acquisitions in 2009, in what it calls a “string of pearls” acquisition strategy.
- M&A activity in the stem cell arena may also kick off in the following quarters of 2009. President Obama has signed an executive order allowing federal taxpayer dollars to fund embryonic stem cell research. International Stem Cells Corporation, the listed US based early-stage stem cell therapeutics company, is viewed as a potential target by a number of large pharmaceutical companies. Venture capitalists are also likely to invest in the space joining the larger Pharma companies interested in boosting their stem cell research efforts.

Global: League Tables of Financial Advisers

Financial Advisers to Global Life Sciences & Healthcare M&A: Value

Rank	House	Value (US\$m)	Deal Count
1	Goldman Sachs	161,380	10
2	Morgan Stanley	111,918	6
3	JPMorgan	107,701	5
4	Bank of America Merrill Lynch	66,127	6
5	Barclays Bank	65,329	2
6	Citigroup	64,115	2
7	Evercore Partners	64,015	1
8	Greenhill & Co	47,120	1
9	UBS Investment Bank	3,591	5
10	Deutsche Bank	1,059	3
11	Credit Suisse	790	1
12	Piper Jaffray & Co	744	2
13=	Pohjola Corporate Finance	417	1
13=	SEB Enskilda	417	1
15	BMO Capital Markets	384	1
16	Moelis & Company	275	1
17	Jefferies & Company	185	1
18	RBC Capital Markets	142	2
19	DnB NOR	119	2
20	Seymour Pierce	94	1

Financial Advisers to Global Life Sciences & Healthcare M&A: Volume

Rank	House	Value (US\$m)	Deal Count
1	Goldman Sachs	161,380	10
2	Morgan Stanley	111,918	6
3	Bank of America Merrill Lynch	66,127	6
4	JPMorgan	107,701	5
5	UBS Investment Bank	3,591	5
6	Deutsche Bank	1,059	3
7	Rothschild	37	3
8	Barclays Bank	65,329	2
9	Citigroup	64,115	2
10	Piper Jaffray & Co	744	2
11	RBC Capital Markets	142	2
12	DnB NOR	119	2
13	KPMG	46	2
14	Lazard	35	2
15	Leerink Swann & Company	27	2
16	William Blair & Company	26	2
17	Deloitte	25	2
18	Global M&A	18	2
19	Evercore Partners	64,015	1
20	Greenhill & Co	47,120	1

Global: League Tables of Financial Advisers

Financial Advisers to Mid-Market Life Sciences & Healthcare M&A: Value

Rank	House	Value (US\$m)	Deal Count
1	JPMorgan	488	3
2	Bank of America Merrill Lynch	428	3
3=	Jefferies & Company	185	1
3=	UBS Investment Bank	185	1
5	Deutsche Bank	159	2
6	RBC Capital Markets	142	2
7	DnB NOR	119	2
8	Citigroup	100	1
9	Seymour Pierce	94	1
10=	Haitong Securities	90	1
10=	Sequoia	90	1
12=	Ferghana Partners	58	1
12=	Royal Bank of Scotland Group	58	1
14	KPMG	46	1
15	Piper Jaffray & Co	44	1

Financial Advisers to Mid-Market Life Sciences & Healthcare M&A: Volume

Y/E 2008	House	Value (US\$m)	Deal Count
1	JPMorgan	488	3
2	Bank of America Merrill Lynch	428	3
3	Deutsche Bank	159	2
4	RBC Capital Markets	142	2
5	DnB NOR	119	2
6	Rothschild	37	2
7	Lazard	35	2
8	Leerink Swann & Company	27	2
9=	Jefferies & Company	185	1
9=	UBS Investment Bank	185	1
11	Citigroup	100	1
12	Seymour Pierce	94	1
13=	Haitong Securities	90	1
13=	Sequoia	90	1
15	Ferghana Partners	58	1

*Mid-Market based on deal value range of US\$ 10m - US\$ 250m

Global: League Tables of Legal Advisers



Legal Advisers to Global Life Sciences & Healthcare M&A: Value

Rank	House	Value (US\$m)	Deal Count
1	Skadden Arps Slate Meagher & Flom	158,287	8
2	Wachtell, Lipton, Rosen & Katz	107,213	2
3	Sullivan & Cromwell	91,322	4
4	Davis Polk & Wardwell	91,108	3
5	Dewey & LeBoeuf	67,227	5
6	Clifford Chance	65,329	4
7	Stikeman Elliott	64,399	2
8	Paul Weiss Rifkind Wharton & Garrison	64,115	3
9=	Cadwalader, Wickersham & Taft	64,015	1
9=	Debevoise & Plimpton	64,015	1
9=	Simpson Thacher & Bartlett	64,015	1
12	Latham & Watkins	52,522	9
13	Cravath Swaine & Moore	48,720	6
14	Wilson Sonsini Goodrich & Rosati	48,045	3
15	Freshfields Bruckhaus Deringer	47,788	2
16	Homburger	47,120	1
17	Shearman & Sterling	46,157	3
18	Cleary Gottlieb Steen & Hamilton	44,448	5
19	Fried Frank Harris Shriver & Jacobson	43,328	3
20	Blake, Cassels & Graydon	43,198	2

Legal Advisers to Global Life Sciences & Healthcare M&A: Volume

Rank	House	Value (US\$m)	Deal Count
1	Latham & Watkins	52,522	9
2	Skadden Arps Slate Meagher & Flom	158,287	8
3	Cravath Swaine & Moore	48,720	6
4	Jones Day	2,894	6
5	Dewey & LeBoeuf	67,227	5
6	Cleary Gottlieb Steen & Hamilton	44,448	5
7	Sullivan & Cromwell	91,322	4
8	Clifford Chance	65,329	4
9	Morgan Lewis & Bockius	1,097	4
10	Linklaters	417	4
11	Goodwin Procter	247	4
12	Davis Polk & Wardwell	91,108	3
13	Paul Weiss Rifkind Wharton & Garrison	64,115	3
14	Wilson Sonsini Goodrich & Rosati	48,045	3
15	Shearman & Sterling	46,157	3
16	Fried Frank Harris Shriver & Jacobson	43,328	3
17	Cooley Godward Kronish	1,443	3
18	White & Case	815	3
19	Ropes & Gray	390	3
20	Bingham McCutchen	293	3

Global: League Tables of Legal Advisers

Legal Advisers to Mid-Market Life Sciences & Healthcare M&A: Value			
Rank	House	Value (US\$m)	Deal Count
1	Latham & Watkins	587	4
2	Linklaters	417	4
3	Cravath Swaine & Moore	286	3
4=	Blake Dawson	248	1
4=	Corrs Chambers Westgarth	248	1
4=	Hogan & Hartson	248	1
4=	Proskauer Rose	248	1
4=	Shearman & Sterling	248	1
9	Goodwin Procter	247	3
10=	Cleary Gottlieb Steen & Hamilton	225	1
10=	Wilson Sonsini Goodrich & Rosati	225	1
12=	Dewey & LeBoeuf	197	2
12=	Morgan Lewis & Bockius	197	2
14	Skadden Arps Slate Meagher & Flom	185	1
15	Fried Frank Harris Shriver & Jacobson	130	1

Legal Advisers to Mid-Market Life Sciences & Healthcare M&A: Volume			
Rank	House	Value (US\$m)	Deal Count
1	Latham & Watkins	587	4
2	Linklaters	417	4
3	Cravath Swaine & Moore	286	3
4	Goodwin Procter	247	3
5	Schjodt	120	3
6=	Dewey & LeBoeuf	197	2
6=	Morgan Lewis & Bockius	197	2
8	Cooley Godward Kronish	129	2
9	Ropes & Gray	115	2
10=	Plesner	101	2
10=	Wiersholm	101	2
12	Eubelius	35	2
13=	Greenberg Traurig	34	2
13=	WilmerHale	34	2
15	Herbert Smith/Gleiss Lutz/Stibbe	31	2

*Mid-Market based on deal value range of US\$ 10m - US\$ 250m

Global: League Tables Analysis



Comparative Analysis of Top Financial Advisers Global Vs LS&H - Q1 2009

Global Rank	LS&H Rank	House	Global Value (US\$m)	LS&H Value (US\$m)	LS&H % of Global Value	Global Deal Count	LS&H Deal Count	LS&H % of Global Volume	Activity Ranking Global
1	1	Goldman Sachs	198,568	161,380	81.3%	38	10	26.3%	6
2	2	Morgan Stanley	178,708	111,918	62.6%	47	6	12.8%	1
3	3	JPMorgan	166,910	107,701	64.5%	45	5	11.1%	2
4	4	Bank of America Merrill Lynch	116,241	66,127	56.9%	41	6	14.6%	3
7	5	Barclays Bank	81,543	65,329	80.1%	6	2	33.3%	34
5	6	Citigroup	112,616	64,115	56.9%	35	2	5.7%	8
8	7	Evercore Partners	64,170	64,015	99.8%	4	1	25.0%	47
10	8	Greenhill & Co	47,470	47,120	99.3%	2	1	50.0%	85
12	9	UBS Investment Bank	36,306	3,591	9.9%	41	5	12.2%	4
6	10	Deutsche Bank	85,369	1,059	1.2%	29	3	10.3%	12
9	11	Credit Suisse	54,415	790	1.5%	34	1	2.9%	9
13	28	Rothschild	33,198	37	0.1%	38	3	7.9%	7
11	29	Lazard	38,415	35	0.1%	39	2	5.1%	5

Life Sciences provides lifeline for advisors

To understand just how crucial the “mega” Life Sciences & Healthcare (LS&H) deals have been to the financial advisory community, one need not look further than mergermarket's top 10 rankings of financial advisers to global M&A. Four out of ten firms reported a quarter of deal activity in this sector alone, including number one ranked Goldman Sachs at 26%. In addition, for only two of the top 10 firms LS&H did not represent at least 50% of their overall total. For Evercore Partners and Greenhill & Co LS&H represented as much as 99% of overall value.

The only firms that managed to buck this trend were Deutsche Bank and Credit Suisse. Deutsche, on a total LS&H value of just over US\$ 1bn (or 1% of its overall value) is ranked 6th overall on a value of \$ 85bn – apparently not a favourite within the Life Sciences community.

What is interesting is that apart from the large LS&H deals, most of the top 10 advisers appeared to have worked on predominantly small deals - JPMorgan being a prime example of this. The firms LS&H deals represent 65% of its overall M&A value, while the actual number of deals worked on in the sector only represent 11% of JP's total activity in the quarter. Similar numbers can be seen with Morgan Stanley (63% of overall value) and Bank of America Merrill Lynch (57% of overall value) at 13% and 15%, respectively.

So is there a loser in these scenarios? On the one hand, one might argue Deutsche or Credit Suisse missed out on advising on the deals that made all the headlines so far this year, hampering their chances of a top three finish – while on the other hand it shows that they were mandated on most of the larger deals outside of the sector, whereas their peers were not – specialization vs diversification?

There does however appear to be one big loser, Lazard. The firm was the 5th most active firm in the quarter but only ranks 11th overall in terms of value on US\$ 38bn worth of deals, while the firms LS&H ranking is a mediocre 29th working on only 2 deals worth US\$ 35m. Ironically, the one lapsed deal in the top 15 LS&H deals, Astellas Pharma's US\$1bn acquisition of CV Therapeutics (losing out to Gilead Sciences' US\$1.3bn bid), had Lazard as sole buy side adviser.

Global: Top Announced Deals Q1 2009



Top 10 Announced Global Life Sciences & Healthcare Deals Q1 2009

Announced Date	Target Company	Target/Seller Financial Adviser	Target/Seller Legal Adviser	Bidder Company	Bidder Financial Adviser	Bidder Legal Adviser	Seller Company	Deal Value (US\$m)
26-Jan-09	Wyeth	Evercore Partners; Morgan Stanley	Dewey & LeBoeuf (Advising Evercore Partners); Paul Weiss Rifkind Wharton & Garrison (Advising Morgan Stanley); Simpson Thacher & Bartlett; Stikeman Elliott; Wachtell, Lipton, Rosen & Katz	Pfizer Inc	Bank of America Merrill Lynch; Barclays Bank; Citigroup; Goldman Sachs; JPMorgan	Cadwalader, Wickersham & Taft; Clifford Chance; Debevoise & Plimpton (Advising Barclays Bank); Skadden Arps Slate Meagher & Flom (Advising Bank of America Merrill Lynch; Goldman Sachs; JPMorgan)		64,015
30-Jan-09	Genentech Inc (44.10% stake)	Goldman Sachs	Cravath Swaine & Moore (Advising Goldman Sachs); Latham & Watkins; Wilson Sonsini Goodrich & Rosati	Roche Holding Ltd	Greenhill & Co	Davis Polk & Wardwell; Freshfields Bruckhaus Deringer; Homburger; Skadden Arps Slate Meagher & Flom (Advising Greenhill & Co); Sullivan & Cromwell (Advising Greenhill & Co)		47,120
09-Mar-09	Schering Plough Corporation	Goldman Sachs; Morgan Stanley	Blake, Cassels & Graydon; Shearman & Sterling (Advising Morgan Stanley); Skadden Arps Slate Meagher & Flom; Sullivan & Cromwell (Advising Goldman Sachs); Wachtell, Lipton, Rosen & Katz	Merck & Co Inc	JPMorgan	Cleary Gottlieb Steen & Hamilton; Davis Polk & Wardwell (Advising JPMorgan); Fried Frank Harris Shriver & Jacobson		43,198
12-Jan-09	Advanced Medical Optics Inc	Goldman Sachs; UBS Investment Bank	Dewey & LeBoeuf (Advising UBS Investment Bank); Latham & Watkins (Advising Goldman Sachs); Skadden Arps Slate Meagher & Flom	Abbott Laboratories	Morgan Stanley	Baker & McKenzie; Jones Day; and Shearman & Sterling (Advising Morgan Stanley)		2,711
12-Mar-09	CV Therapeutics Inc	Barclays Bank; Goldman Sachs	Clifford Chance (Advising Barclays Bank); Cravath Swaine & Moore (Advising Goldman Sachs); Latham & Watkins	Gilead Sciences Inc	Bank of America Merrill Lynch	Cooley Godward Kronish; Willkie Farr & Gallagher (Advising Bank of America Merrill Lynch)		1,314
27-Feb-09*	CV Therapeutics Inc	Barclays Bank; Goldman Sachs	Clifford Chance (Advising Barclays Bank); Cravath Swaine & Moore (Advising Goldman Sachs); Latham & Watkins	Astellas Pharma Inc	Lazard	Gibson Dunn & Crutcher (Advising Lazard); Morrison & Foerster		1,057
09-Feb-09	OVATION Pharmaceuticals Inc	Goldman Sachs; Morgan Stanley	Katten Muchin Rosenman; Kirkland & Ellis	Lundbeck Research USA Inc	Deutsche Bank	Morgan Lewis & Bockius	GTCR Golder Rauner LLC	900
27-Feb-09	Mishima Olympus Co Ltd; Olympus Corporation (Diagnostic Systems division); and Olympus Medical Engineering Co Ltd	<i>Advising Seller:</i> Credit Suisse	<i>Advising Seller:</i> Gide Loyrette Nouel; Squire, Sanders & Dempsey; William Fry	Beckman Coulter Inc	Morgan Stanley	Davis Polk & Wardwell (Advising Morgan Stanley); Latham & Watkins; White & Case	Olympus Corporation	790
23-Feb-09	CoreValve Inc	Goldman Sachs	Sullivan & Cromwell (Advising Goldman Sachs); Wilson Sonsini Goodrich & Rosati	Medtronic Inc	Piper Jaffray & Co	Cleary Gottlieb Steen & Hamilton; Fredrikson & Byron	Apax Partners; HealthCap; Maverick Capital Ltd; and Sofinnova Partners	700
23-Jan-09	UCB SA (product portfolio)			GlaxoSmithKline	Goldman Sachs	Allen & Gledhill; Freshfields Bruckhaus Deringer; LCS & Partners; NautaDutilh; Slaughter and May	UCB SA	668

*Denotes lapsed deal

Global: Top Announced Mid-Market Deals Q1 2009

Top 10 Announced Mid-Market Global Life Sciences & Healthcare Deals Q1 2009								
Announced Date	Target Company	Target/Seller Financial Adviser	Target/Seller Legal Adviser	Bidder Company	Bidder Financial Adviser	Bidder Legal Adviser	Seller Company	Deal Value (US\$m)
13-Feb-09	HeartWare International Inc	JPMorgan	Blake Dawson; Cravath Swaine & Moore (Advising JPMorgan); Hogan & Hartson; Shearman & Sterling; <i>Advising seller: Proskauer Rose</i>	Thoratec Corporation	Bank of America Merrill Lynch	Corrs Chambers Westgarth; Latham & Watkins	Apple Tree Partners I LP	248
12-Jan-09	Ablation Frontiers Inc	JPMorgan	Linklaters; Wilson Sonsini Goodrich & Rosati	Medtronic Inc		Cleary Gottlieb Steen & Hamilton		225
19-Mar-09	ACON Laboratories Inc (Second Territory Rapid diagnostics business)			Inverness Medical Innovations Inc		Goodwin Procter	ACON Laboratories Inc	200
3-Feb-09	PharmaNet Development Group Inc	UBS Investment Bank	Dewey & LeBoeuf (Advising UBS Investment Bank); Latham & Watkins; Morgan Lewis & Bockius	JLL Partners	Jefferies & Company	Skadden Arps Slate Meagher & Flom		185
12-Feb-09	Insmed (Follow-on Biologics Platform)	Advising seller: RBC Capital Markets	<i>Advising seller: McGuireWoods; O'Melveny & Myers (Advising RBC Capital Markets)</i>	Merck & Co Inc		Fried Frank Harris Shriver & Jacobson	Insmed Incorporated	130
12-Jan-09	Clinique Cap d'Or; Clinique Saint Michel; Clinique Saint Vincent; La Belle Gensiere; Polyclinique les Fleurs; and Soleil d'Or	Internal	Binisti Bouquet Lassalle & Associes; Cabinet des Avocats Becque Monestier et Dahan	Medi Partenaires	Internal	Gatienne Brault & Associates		107
23-Feb-09	MediCult AS	DnB NOR	Plesner; Wiersholm	Merck KGaA	Deutsche Bank	Kromann Reumert; Thommessen		101
25-Feb-09	Geodigm Corporation (majority stake)	Citigroup	Lindquist & Vennum; Paul Weiss Rifkind Wharton & Garrison	Welsh, Carson, Anderson & Stowe	Internal	Ropes & Gray		100
12-Feb-09	Presbyterian Hospital (80% stake)			Texas Health Resources			Triad-Denton Hospital Gp LLC; and Triad-Denton Hospital LP	100
30-Jan-09	Tepnel Life Sciences Plc	Seymour Pierce	Halliwells	Gen-Probe Incorporated	Bank of America Merrill Lynch	Cooley Godward Kronish; Latham & Watkins (Advising Bank of America Merrill Lynch); Linklaters		94

Global: Expected Deals



Potential Targets for Sale - Life Sciences & Healthcare Deals					
Target Company	Target Country	Vendor	Intelligence	Deal Value (US\$m)	Intelligence
Stiefel Laboratories Inc	US	Stiefel family, Blackstone Group	Strong evidence	4,000	"Stiefel Laboratories, the private Florida-based dermatology pharmaceutical company, is studying putting itself on the block, reported the Wall Street Journal. The report, which cited sources privy to the process, said that large pharmaceuticals such as listed UK-based GlaxoSmithKline, listed Swiss Novartis and listed New Jersey-based Johnson & Johnson are interested. The report's sources valued the deal at US\$ 3bn - US\$ 4bn."
Ratiopharm GmbH	Germany	Merckle family, Merckle GmbH	Confirmed	3,984	"Ratiopharm, the German generic drug maker, will be sold by 2010, Boersen-Zeitung reported. The German daily cited the company as saying the sale is intended to be completed by the first quarter of 2010. It has not held any talks with investors yet, and this is not expected to happen before the summer, the company was cited as saying. The report went on to say, without naming sources, that companies that have been mentioned as possible buyers include GlaxoSmithKline, Pfizer, Sanofi-Aventis, Teva and DaiichiSankyo. The report noted that last year, Ratiopharm had a turnover of EUR 1.9bn."
Coventry Health Care Inc	US	-	Strong evidence	1,800	Coventry Health Care, the Bethesda, Maryland healthcare company, is facing speculation it could be a takeover target, reported the Wall Street Journal. The report, part of the paper's option trading column, cited traders as saying Coventry Health Care could be a target.
Schering-Plough's over-the-counter (OTC) business*	US	Merck	Confirmed	1,300	Merck, the Whitehouse Station, New Jersey-based pharmaceutical company, likely will divest Schering-Plough's over-the-counter (OTC) business it stands to gain from the planned merger between the two companies, said a healthcare banker and consumer banker.
Cooper Companies *	US	-	Strong evidence	1,180	As The Cooper Companies continues its strategy of utilizing cash to pay down debt, sources familiar with the company said a shortlist of M&A suitors could be eyeing the pure-play contact lens player. Cooper's CFO Eugene Midlock declined to comment on whether the company has been approached or has run a process. However, Albert White, VP of investor relations at Cooper, responded that "a lot of bankers pitch different ideas, different structures and so forth, but we don't comment on any acquisition information or news."
Four Seasons Healthcare	UK	-	Rumoured	1,000	"Four Seasons Healthcare is set to hire Deutsche Bank in preparation for a sale which could be worth as much as GBP 1bn (EUR 1.1bn), the Financial Times reported. The report did not cite a source for the information but said the indebted British care-homes operator could prove attractive to American trade buyers, private-equity firms, or companies based in India and China which hope to expand their global presence. Four Seasons will continue its restructuring negotiations with creditors over its GBP 1.5bn debt, the report said. However, it added that the group hopes a sale may prove faster than resolving complicated debt-restructure talks."
Zeltia SA	Spain	-	Rumoured	862	Zeltia, the listed Spanish biotechnology group, is seen as a possible takeover target for a large US pharmaceutical company, La Gaceta reported. The report, in a column about market rumours, did not give any details of potential bidders. Zeltia's market capitalisation stands at EUR 662.17m
SIA International Ltd	Russia	Igor Rudinskiy (private investor)	Confirmed	800	SIA-International's controlling shareholder Igor Rudinskiy is seeking a new buyer for the privately held Russian pharmaceutical distributor, as TPG Capital fails to close the deal. A report in Kommersant cited Rudinskiy as saying that he no longer considers himself bound with obligations towards TPG. TPG was supposed to pay around USD 800m for a 50% stake minus one share, by 31 December 2008, but until now, the deal has not been finalised.

*Denotes mergermarket proprietary intelligence

Global: Expected Deals





Anticipated Life Sciences & Healthcare Auctions					
Target Company	Target Country	Vendor	Intelligence	Deal Value (US\$m)	Intelligence
Solvay Pharmaceuticals SA	Belgium	Solvay SA	Strong evidence	6,600	Solvay, the Belgian conglomerate, has had initial talks to sell its pharmaceutical division, the Wall Street Journal reported citing sources privy to the process. According to the report the sale could begin this month. The unit could fetch US\$ 5bn - US\$ 6.6bn, the report said. Possible buyers cited by the report include Bayer, Sanofi-Aventis, Abbott Laboratories, AstraZeneca and Merck KGaA.
Elan Drug Technology	Ireland (Republic)	Elan Corporation Plc	Rumoured	1,342	Elan, the Dublin, Ireland-based biotechnology company, could once again put its drug technology unit up for sale, reported Investor's Digest of Canada in its 10 April issue. Neil Maruoka, an analyst with Canaccord Adams, said in a research note cited in the investment advisory that Elan could address its debt-load problems by selling the division to raise some much-needed cash.
Galenika a.d.	Serbia & Montenegro	Government of the Republic of Serbia, Serbian Privatization Agency	Strong evidence	796	"A sale tender for a 70% stake in Galenika, the Serbian state-owned pharmaceutical company, could be launched in June, the Executive Newsletter reported. The report cited local media which in turn cited unnamed sources in the Serbian Privatisation Agency (PA). The process for the selection of a privatisation adviser for Galenika is still in progress, the report said, adding that the most probable winner will be a consortium led by Rothschild & Cie. Galenika has an estimated value of up to EUR 600m, an earlier report said."



Potential Life Sciences & Healthcare Deals					
Target Company	Target Country	Vendor	Intelligence	Deal Value (US\$m)	Intelligence
Chongqing Medicines Co. Ltd	China	China National Pharmaceutical Group Corporation	Strong evidence	1,162	Sinopharm [Guo Yao Ji Tuan], the Beijing-based pharmaceutical distribution company, is planning to take over Chongqing Medicine [Chong Qing Yi Yao], the China Times reported. The paper cited an unnamed source who said the two companies are currently in talks over the deal. Chongqing Medicine is a Chongqing-based medical products distribution and sales company, and is the seventh largest in mainland China. The source said that a preliminary agreement has been reached, but the two companies have disagreements over the deal value. According to the source, Sinopharm will take a controlling interest in Chongqing Medicine.
Kalbe Farma Tbk PT	Indonesia	Undisclosed Bidder	Rumoured	538	Kalbe Farma, the listed Indonesian pharmaceuticals company, is being targeted by an unspecified French company, reported Kontan. The report cited an unnamed source who said that an unspecified France-based pharmaceuticals company is targeting Kalbe Farma as part of its business expansion plan in Indonesia. The unspecified bidder is aiming to sell its French-made medicines in the Indonesian market, added the source. The acquisition of Kalbe Farma is seen as a more feasible option than forming a new company in Indonesia, the source said. Kalbe Farma is Indonesia's largest pharmaceuticals company, with more than 10,000 employees, and has a market cap of IDR 6.3tn (US\$ 538m).
Shantha Biotechnics Limited	India	Sanofi-Aventis; GlaxoSmithKline	Rumoured	238	"Shantha Biotech, the unlisted Indian biotech company, is being eyed for a buyout by listed pharma companies France-based Sanofi-Aventis and UK-headquartered GlaxoSmithKline. A report in The Economic Times cited an unidentified source as saying that Merieux Alliance, the privately-held French biotech company that is a majority owner of Shantha Biotech, is in talks with the two multinationals to sell its 80% holding."
Santarus, Inc.*	US	Cosmo Pharmaceuticals s.p.a.	Confirmed	223	Cosmo Pharma, the Swiss listed, Italian headquartered pharma company, is interested in taking over NASDAQ-listed Santarus (San Diego, CA), chief executive officer Mauro Ajani said. The two companies have already discussed merger options, which could lead to an integrated group where Cosmo would be responsible for drug development and production, and Santarus would look after marketing and distribution, the CEO noted. Ajani did not provide a timeline for such an operation to occur.
Concateno Plc	UK	-	Confirmed	143	Concateno yesterday revealed it is in advanced-stage negotiations with a potential buyer, the Financial Times said in a market report. An excerpt from the UK-listed testing specialist's preliminary results follows: The Company remains in an active Offer Period which may or may not lead to an offer being made for the Company. Discussions with possible offerors are at an advanced stage and Concateno expects to be able to announce its conclusion in the relative short term.

*Denotes mergermarket proprietary intelligence

Global: M&A Activity Trend




Global: M&A Activity Trend




Global: M&A Activity Trend



Global M&A Life Sciences & Healthcare Deal Size Breakdown (value)




Global M&A Life Sciences & Healthcare Deal Size Breakdown (volume)




Global: Breakdown of Announced Deals Q1 2009


Global M&A Sector Breakdown Q1 2009- Value




Global M&A Sector Breakdown Q1 2009- Volume



Geographical breakdown of Life Sciences & Healthcare sector - Q1 2009 (value)



Geographical breakdown of Life Sciences & Healthcare sector - Q1 2009 (volume)



Criteria



The global Q1 2009 house league tables are based on announced transactions over US\$ 5m in the period from **1 January 2009 to 31 March 2009**. Deals with undisclosed deal values are included where the target's turnover exceeds US\$ 10m. Deals where the stake acquired is less than 30% will only be included if their value is greater than US\$ 100m. Activities excluded from the league tables include property transactions and restructurings where the ultimate shareholders' interests are not changed. League tables are based on the dominant geography of the target, bidder or seller.

The global Life Sciences & Healthcare Q1 2009 house league tables are based on announced transactions over US\$ 5m in the period from 1 January 2009 to 31 March 2009. Deals with undisclosed deal values are included where the target's turnover exceeds US\$ 10m. Deals where the stake acquired is less than 30% will only be included if their value is greater than US\$ 100m. Activities excluded from the league tables include property transactions and restructurings where the ultimate shareholders' interests are not changed. League tables are based on the dominant sector of the target, bidder or seller.

Rankings are based on the advisory firms advising either target, bidder or seller companies, unless stated otherwise.

The trend graphs and pie charts are based on the dominant industry and/or dominant geography of the target and include announced transactions over US\$ 5m in the given time period. Deals with undisclosed deal values are included where the target's turnover exceeds US\$ 10m. Deals where the stake acquired is less than 30% will only be included if their value is greater than US\$ 100m. Activities excluded from the graphs and charts include property transactions and restructurings where the ultimate shareholders' interests are not changed.

The top deals tables are based on announced transactions between 1 January 2009 and 31 March 2009 and are based on dominant sector of the target only.

The average M&A 1-day before bid premium analysis contains averages per quarter where outliers have been manually removed. Deals included in the sample are based on tender offers where the dominant sector of the target company is Life Sciences & Healthcare.

Unless stated otherwise, all data excludes lapsed and withdrawn bids.

All data correct as of 17 April 2009.

About mergermarket

mergermarket is a mergers & acquisitions (M&A) intelligence service.

mergermarket is part of The Mergermarket Group which has over 450 employees worldwide and regional head offices in New York, London and Hong Kong.

In any market, the life blood of advisers is deal flow. mergermarket is unique in the provision of origination intelligence to the investment banking, PR, private equity, acquisition finance, public relations (PR) and corporate markets.

With an unrivalled network of analysts covering M&A in the Americas, Europe, Middle-East, Africa and Asia-Pacific, mergermarket generates proprietary intelligence and delivers it together with daily aggregated content, on its mergermarket.com platform and by real-time email alerts to subscribers.

This wealth of intelligence, together with a series of deal databases, individual and house league tables, profiles and editorial have proven time and time again that this product can and does generate real revenues for clients. This is apparent when you see that mergermarket is used by over 1500 of the world's foremost advisory firms to assist in their origination process.

part of The Mergermarket Group

www.mergermarket.com

Strand
London, WC2R 0RL
United Kingdom

+44 (0)20 7059 6100
+44 (0)20 7059 6101
les@mergermarket.com

11 West 19th Street
4th Floor
New York
NY 10011, USA

t: +1 212-686-5606
f: +1 212-686-2664
sales.us@mergermarket.com

Suite 2001
Grand Millennium Plaza
181 Queen's Road, Central
Hong Kong

t: +852 2158 9700
f: +852 2158 9701
sales.asia@mergermarket.com

Contact:

Europe & North America:

Hannah Bagshawe

hannah.bagshawe@mergermarket.com

Tel: +44 20 7059 6118

Asia-Pacific:

Seye Im

seye.im@mergermarket.com

Tel: +852 2158 9701